Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Bevacizumab
Bleomycin Sulphate
Carboplatin
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Docetaxelum
Doxorubicinum
Doxorubicinum Liposomanum Pegylatum
Epirubicinum
Etoposidum
Gemcitabine
Ifosfamidum
Imatinibum
Imatinibum (2)
Irinotecanum
Methotrexatum
Paclitaxel
Pazopanib
Sorafenib
Sunitinib
Sunitinib (2)
Tamoxifenum
Temozolomidum
Topotecanum Inj.
Trabectedin
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- sarcoma
- GIST
- » To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma
- » A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
- » Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- » Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
- » A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)